buyModerate cluster of 5
H James Dallas bought $100k of CNC
director at CENTENE CORP. 1,693 shares at an average of $59.01, traded Dec 16, 2024, filed Dec 17, 2024.
Conviction score
48Value
$100k
1,693 shares
Holdings after
1,693
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +10Trade size$100k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001071739-24-000229, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +1,693 | $59.01 | $100k | 1,693 | Dec 17, 2024 |
Related signals
Other insiders at CENTENE CORP and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 65Notable | buy 5 | CNC CENTENE CORP | Thomas Greco director | $1.0M | 17,000 | |
| 38Weak | buy 5 | CNC CENTENE CORP | Jessica L. Blume director | $15k | 250 | |
| 50Moderate | buy 5 | CNC CENTENE CORP | Theodore R. Samuels II director | $294k | 5,000 | |
| 55Moderate | buy 5 | CNC CENTENE CORP | Christopher J Coughlin director | $594k | 10,000 | |
| 55Moderate | buy 2 | CNC CENTENE CORP | Andrew Lynn Asher Chief Financial Officer | $1.0M | 17,200 | |
| 41Moderate | buy 2 | CNC CENTENE CORP | Sarah London Chief Executive Officer | $250k | 4,117 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.